Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
John M. Sharretts, Ovidiu Galescu, Shanti Gomatam, Eugenio Andraca‐Carrera, Christian Hampp, Lisa B. Yanoff
Abstract
In early 2020, the FDA requested that the manufacturer of lorcaserin voluntarily withdraw the drug from the market because of a signal of increased cancer risk. The FDA concluded that the drug’s benefits don’t outweigh its risks for any identifiable patient population.
Topics & Concepts
MedicineTIMIDrugPopulationFood and drug administrationPharmacologyOncologyInternal medicineEnvironmental healthMyocardial infarctionPercutaneous coronary interventionPharmacology and Obesity TreatmentDiabetes Treatment and ManagementMetabolism, Diabetes, and Cancer